REGENXBIO Inc. (RGNX)
Market: NASD |
Currency: USD
Address: 9804 Medical Center Drive
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Show more
📈 REGENXBIO Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$33.15
-
Upside/Downside from Analyst Target:
286.86%
-
Broker Call:
21
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
50-100%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for REGENXBIO Inc.
| Date | Reported EPS |
|---|
| 2026-05-11 (estimated upcoming) | - |
| 2026-03-11 (estimated upcoming) | - |
| 2025-11-04 (estimated upcoming) | - |
| 2025-11-03 (estimated upcoming) | - |
| 2025-07-30 (estimated upcoming) | - |
| 2025-07-29 (estimated upcoming) | - |
| 2025-05-12 | - |
| 2025-05-05 | - |
| 2025-03-13 | -1.01 |
| 2024-11-06 | -1.17 |
| 2024-08-01 | -1.05 |
| 2024-07-31 | -1.05 |
| 2024-05-08 | -1.33 |
| 2024-05-07 | -1.33 |
| 2024-02-27 | -1.43 |
| 2024-02-26 | -1.43 |
| 2023-11-08 | -1.41 |
| 2023-11-07 | -1.41 |
| 2023-08-02 | -1.66 |
| 2023-08-01 | -1.66 |
| 2023-05-03 | -1.53 |
| 2023-05-02 | -1.53 |
| 2023-02-28 | -1.38 |
| 2023-02-27 | -1.38 |
| 2022-11-03 | -1.75 |
| 2022-11-02 | -1.75 |
| 2022-08-03 | -1.58 |
| 2022-08-02 | -1.58 |
| 2022-05-04 | -1.79 |
| 2022-05-03 | -1.79 |
| 2022-03-01 | 6.67 |
| 2022-02-28 | 6.67 |
| 2021-11-02 | -1.37 |
| 2021-11-01 | -1.37 |
| 2021-08-09 | -1.36 |
| 2021-08-08 | -1.36 |
| 2021-05-05 | -1.2 |
| 2021-05-04 | -1.2 |
| 2021-03-01 | -1.24 |
| 2021-02-28 | -1.24 |
| 2020-11-04 | 0.43 |
| 2020-11-03 | 0.43 |
| 2020-08-06 | -0.91 |
| 2020-08-05 | -0.91 |
| 2020-05-07 | -1.08 |
| 2020-05-06 | -1.08 |
| 2020-02-26 | -0.72 |
| 2020-02-25 | -0.72 |
| 2019-11-04 | -0.94 |
| 2019-08-06 | -0.04 |
| 2019-05-06 | -0.89 |
| 2019-02-26 | 0.11 |
| 2018-11-06 | -0.56 |
| 2018-08-07 | 0.3 |
| 2018-05-07 | 3.04 |
| 2018-03-05 | -0.51 |
| 2017-11-07 | -0.67 |
| 2017-08-07 | -0.47 |
| 2017-05-08 | -0.82 |
| 2017-03-06 | -0.74 |
| 2016-11-08 | -0.69 |
| 2016-08-08 | -0.55 |
| 2016-05-04 | -0.41 |
| 2016-03-02 | -0.2 |
| 2015-11-04 | - |
| 2015-09-16 | - |
📰 Related News & Research
No related articles found for "regenxbio inc".
